Form 4: IN8BIO CFO Acquires 343,000 Stock Options
SEC Form 4 Filing
Patrick McCall, CFO of IN8BIO, Inc., reports the acquisition of 343,000 employee stock options on February 5, 2025.
Summary
- Patrick McCall, the Chief Financial Officer of IN8BIO, Inc., filed a Form 4 on February 7, 2025, reporting a transaction.
- On February 5, 2025, McCall acquired 343,000 employee stock options with an exercise price of $0.29.
- These options vest over time, with 25% vesting on February 5, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
- Following the reported transaction, McCall directly owns 343,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a standard practice.
Positives
- The acquisition of stock options by the CFO could indicate confidence in the company's future performance.
Future Outlook
The vesting schedule of the options is contingent upon the Reporting Person continuing to provide service through each such date.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Stakeholder Impact
- The stock option grant could align the CFO's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of the stock option acquisition. |
| 02/05/2026 | Date when 25% of the stock options vest. |
| 02/05/2035 | Expiration date of the stock options. |
| 02/07/2025 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.